AU2016364976B2 - Solid dispersions comprising a sGC stimulator - Google Patents

Solid dispersions comprising a sGC stimulator Download PDF

Info

Publication number
AU2016364976B2
AU2016364976B2 AU2016364976A AU2016364976A AU2016364976B2 AU 2016364976 B2 AU2016364976 B2 AU 2016364976B2 AU 2016364976 A AU2016364976 A AU 2016364976A AU 2016364976 A AU2016364976 A AU 2016364976A AU 2016364976 B2 AU2016364976 B2 AU 2016364976B2
Authority
AU
Australia
Prior art keywords
compound
dispersion
disease
solid dispersion
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016364976A
Other languages
English (en)
Other versions
AU2016364976A1 (en
Inventor
Craig Anthony DUNBAR
Ahmad Hashash
Vasu SETHURAMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyclerion Therapeutics Inc
Original Assignee
Cyclerion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclerion Therapeutics Inc filed Critical Cyclerion Therapeutics Inc
Publication of AU2016364976A1 publication Critical patent/AU2016364976A1/en
Assigned to CYCLERION THERAPEUTICS, INC. reassignment CYCLERION THERAPEUTICS, INC. Request for Assignment Assignors: IRONWOOD PHARMACEUTICALS, INC.
Application granted granted Critical
Publication of AU2016364976B2 publication Critical patent/AU2016364976B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2016364976A 2015-11-30 2016-11-22 Solid dispersions comprising a sGC stimulator Active AU2016364976B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562260910P 2015-11-30 2015-11-30
US62/260,910 2015-11-30
US201662359440P 2016-07-07 2016-07-07
US62/359,440 2016-07-07
PCT/US2016/063312 WO2017095697A1 (en) 2015-11-30 2016-11-22 Solid dispersions comprising a sgc stimulator

Publications (2)

Publication Number Publication Date
AU2016364976A1 AU2016364976A1 (en) 2018-06-14
AU2016364976B2 true AU2016364976B2 (en) 2022-08-25

Family

ID=57590822

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016364976A Active AU2016364976B2 (en) 2015-11-30 2016-11-22 Solid dispersions comprising a sGC stimulator

Country Status (12)

Country Link
US (4) US20190269619A1 (cg-RX-API-DMAC7.html)
EP (1) EP3383372B1 (cg-RX-API-DMAC7.html)
JP (3) JP6952707B2 (cg-RX-API-DMAC7.html)
KR (1) KR102841419B1 (cg-RX-API-DMAC7.html)
CN (4) CN108883071A (cg-RX-API-DMAC7.html)
AU (1) AU2016364976B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018011154B1 (cg-RX-API-DMAC7.html)
CA (1) CA3006746C (cg-RX-API-DMAC7.html)
EA (1) EA201891315A1 (cg-RX-API-DMAC7.html)
IL (2) IL259493B (cg-RX-API-DMAC7.html)
MX (3) MX389961B (cg-RX-API-DMAC7.html)
WO (1) WO2017095697A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017216429B2 (en) * 2016-02-01 2022-10-06 Cyclerion Therapeutics, Inc. Use of sGC stimulators for the treatment of Nonalcoholic Steatohepatitis (NASH)
EA201990237A1 (ru) * 2016-07-07 2019-08-30 Сайклерион Терапьютикс, Инк. Новые способы получения стимуляторов растворимой гуанилатциклазы
MX382762B (es) * 2016-07-07 2025-03-13 Cyclerion Therapeutics Inc Procesos novedosos para preparacion de estimuladores de guanilato ciclasa soluble.
WO2019055859A1 (en) 2017-09-14 2019-03-21 Ironwood Pharmaceuticals, Inc. TREATMENT OF METABOLIC SYNDROME BY SGC STIMULATOR
KR20250048609A (ko) 2018-01-10 2025-04-09 사이클리온 테라퓨틱스, 인크. 가용성 구아닐레이트 시클라제 자극제의 제조를 위한 신규 방법 및 중간체
WO2019161534A1 (en) * 2018-02-22 2019-08-29 Ironwood Pharmaceuticals, Inc. Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators
WO2019172420A1 (ja) * 2018-03-09 2019-09-12 協和発酵キリン株式会社 医薬組成物
KR102755855B1 (ko) * 2018-07-30 2025-01-15 가부시키가이샤 리코 입자의 제조 방법, 및 이 방법에 의해 제조된 입자 및 의약
JP7503781B2 (ja) * 2018-07-30 2024-06-21 株式会社リコー 粒子の製造方法、並びに、それにより製造された粒子及び医薬
US12409140B2 (en) * 2019-09-23 2025-09-09 Bionomics Limited Therapeutic formulations and uses thereof
AU2020372900A1 (en) 2019-10-29 2022-05-26 Cyclerion Therapeutics, Inc. Treatment of diabetic nephropathy with an sGC stimulator
KR20230121867A (ko) * 2020-12-18 2023-08-21 유씨비 바이오파마 에스알엘 무정형 고체 분산체
WO2023009710A1 (en) 2021-07-28 2023-02-02 Cyclerion Therapeutics, Inc. Treatment of hfpef in post-menopausal women with an sgc stimulator

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014144100A2 (en) * 2013-03-15 2014-09-18 Takashi Nakai Sgc stimulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0901786T3 (da) * 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
DE60039379D1 (de) * 1999-02-10 2008-08-21 Pfizer Prod Inc Pharmazeutische feste Dispersionen
KR20140011366A (ko) * 2011-03-08 2014-01-28 잘리커스 파마슈티컬즈 리미티드 고체 분산체 제형 및 그의 이용방법
US9309235B2 (en) * 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
WO2015106268A1 (en) * 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014144100A2 (en) * 2013-03-15 2014-09-18 Takashi Nakai Sgc stimulators

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BROADHEAD J. et al., "The Spray Drying of Pharmaceuticals", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, (1992), vol. 18, no. 11/12, pages 1169 - 1206 *
FRIESEN D. T. et al., "Hydroxypropyl Methylcellulose Acetate Succinate-Based Spray-Dried Dispersions: An Overview", MOLECULAR PHARMACEUTICS, (2008), vol. 5, no. 6, pages 1003 - 1019 *
LEUNER C. et al., "Improving drug solubility for oral delivery using solid dispersions", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., (2000), vol. 50, no. 1, pages 47 - 60 *
TIWARI R. et al., "Solid dispersions: An overview to modify bioavailability of poorly water soluble drugs", INTERNATIONAL JOURNAL OF PHARMTECH RESEARCH, SHPINX KNOWLEDGE HOUSE, (2009), vol. 1, no. 4, pages 1338 - 1349 *

Also Published As

Publication number Publication date
US20250017862A1 (en) 2025-01-16
AU2016364976A1 (en) 2018-06-14
MX2022001655A (es) 2022-03-11
US20190269619A1 (en) 2019-09-05
US20250255821A1 (en) 2025-08-14
KR102841419B1 (ko) 2025-08-01
MX389961B (es) 2025-03-20
EP3383372B1 (en) 2023-11-01
CN116637077A (zh) 2023-08-25
IL290338A (en) 2022-04-01
IL259493A (en) 2018-07-31
JP2022000464A (ja) 2022-01-04
BR112018011154A2 (pt) 2018-11-21
JP2023100851A (ja) 2023-07-19
IL259493B (en) 2022-03-01
US20240293324A1 (en) 2024-09-05
JP7277534B2 (ja) 2023-05-19
IL290338B1 (en) 2023-01-01
IL290338B2 (en) 2023-05-01
CA3006746A1 (en) 2017-06-08
CA3006746C (en) 2024-01-30
EP3383372A1 (en) 2018-10-10
BR112018011154B1 (pt) 2023-09-26
MX2022001656A (es) 2022-03-11
JP6952707B2 (ja) 2021-10-20
CN116637076A (zh) 2023-08-25
JP7641320B2 (ja) 2025-03-06
EA201891315A1 (ru) 2018-12-28
CN108883071A (zh) 2018-11-23
KR20180086497A (ko) 2018-07-31
WO2017095697A1 (en) 2017-06-08
CN116942616A (zh) 2023-10-27
JP2019501216A (ja) 2019-01-17

Similar Documents

Publication Publication Date Title
US20250255821A1 (en) Solid dispersions comprising a sgc stimulator
CN111818918B (zh) 用于治疗囊性纤维化的药物组合物
JP5017115B2 (ja) ４−（４−（３−（４−クロロ−３−トリフルオロメチルフェニル）ウレイド）−３−フルオロフェノキシ）ピリジン−２−カルボン酸を含んでなる過剰増殖性疾患の治療のための新規薬剤組成物
US20210228489A1 (en) Compositions for treating cystic fibrosis
US10590089B2 (en) Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
WO2001095912A1 (fr) Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph
WO2020242935A1 (en) Methods of treatment for cystic fibrosis
HK1261747B (en) Solid dispersions comprising a sgc stimulator
HK1261747A1 (en) Solid dispersions comprising a sgc stimulator
RU2822220C2 (ru) Фармацевтические композиции для лечения муковисцидоза
EA043018B1 (ru) Твердые дисперсии, содержащие стимулятор sgc, для применения в качестве лекарственного средства

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CYCLERION THERAPEUTICS, INC.

Free format text: FORMER APPLICANT(S): IRONWOOD PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)